98%
921
2 minutes
20
With a 0.5 kb probe of CX2, distribution of CX2 tandem repeats was studied in different C.albicans strains. Results suggest that all the C.albicans strains tested contained the tandem repeat. In order to verify if the expression of CX2 was hyphal specific, its expression was analyzed under various inductive and non-inductive conditions. With CX2 0.5 kb probe, Northern hybridization analysis confirmed that it was specifically in hyphae. The result of chromosomal localizationtion and genomic Southern blot analysis suggested that there were other genes containing the tandem repeat besides of ALS1. A C.albicans s genomic DNA library was screened with the CX2 0.5 kb probe and several positive recombinant lambda phages were obtained. After endonuclease identification, subcloning, and sequence analysis, several ALS family genes were cloned. No.1 lambda phage DNA contained ALS4, No.4 lambda phage DNA contained ALS1, No.6 lambda phage DNA contained ALS3. To study the role of ALS family genes in yeast-hyphal transition, als1/ALS1 mutant was constructed by homologous recombination. The ability to form hyphae was tested in different inductive culturing conditions. Defective hyphal growth were observed in some solid media.
Download full-text PDF |
Source |
---|
Immunotherapy
September 2025
Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFAnn Clin Transl Neurol
September 2025
Department of Neurology, Brain Centre Utrecht, University Medical Centre Utrecht, Utrecht, the Netherlands.
Objective: We investigated the effects of C9orf72 mutation carriership on peripheral nerve excitability in asymptomatic individuals from families with a history of C9orf72 amyotrophic lateral sclerosis (ALS) and patients.
Methods: We included 47 asymptomatic individuals from families with a history of C9orf72 ALS, of whom 23 were carriers (C9) and 24 were noncarriers (C9). In addition, 11 C9 and 110 C9 ALS patients and 50 healthy controls participated.
Palliat Med
September 2025
Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK.
Background: There is growing demand for home-based palliative care because of patient preference, and increased number of deaths. Optimal models for community-based palliative and end-of-life care are unknown.
Aim: To identify, synthesise and describe review-level evidence to better understand models of palliative and end-of-life care for adults living at home, and examine components of these models and their association with outcomes.
Protein Pept Lett
September 2025
Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, Karnataka, 560111, India.
Introduction: Neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS are characterized by progressive neuronal dysfunction with limited therapeutic options. Recent advances in molecular biology and drug development have highlighted the therapeutic promise of precision enzyme targeting, offering novel strategies for disease modulation and symptom management.
Methods: A comprehensive literature review spanning recent/current was conducted using PubMed, Scopus, and ScienceDirect.
Nervenarzt
September 2025
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland.